Targeting the PI3K/AKT/PTEN Pathway in HR+/HER2- Locally Advanced and Metastatic Breast Cancer : Episode 2
Opinion
Video
First-Line Treatment Options in HR+/HER2- and Challenges with Treatment Resistance
Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, delve into the most clinically significant genomic tests and biomarker assays employed in HR+/HER2- breast cancer, focusing on BRCA mutations, PI3 alterations, AKT alterations, and PTEN alterations, which play crucial roles in determining prognosis and guiding treatment decisions.
- What is your approach to selecting a first-line treatment options for HR+/HER2- breast cancer? Please provide a high-level overview of SOC treatment options in the first-line?
- What are primary considerations in selecting a first-line treatment?
- What proportion of patients with HR+/HER2- breast cancer experience resistance to first-line endocrine therapy (ET) + CDK4/6 inhibitor?
- What does disease progression after first-line treatment look like?
- What is the typical timing of disease progression after first-line treatment?
Related Videos
Related Content
